Original Article
Efficacy and safety of apatinib in patients with metastatic colorectal cancer refractory to standard therapies
Abstract
Background: To evaluate the efficacy and safety of apatinib in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Methods: Patients with refractory mCRC received 500 mg of apatinib once a day in a 28-day cycle. Response was assessed using the RECIST 1.1 criteria, and toxicity was graded using CTCAE version 4.03. Survival analysis was performed by Kaplan-Meier method.
Results: Forty-one patients were included in the present study. Among these patients, 4 patients achieved partial response and 27 achieved stable disease. The response rate was 9.8%, and disease control rate was 75.6%. Median progression-free survival and overall survival were 2.9 months (95% CI: 2.4–3.5) and 8.9 months (95% CI: 8.0–9.8), respectively. The grade 3/4 toxicities observed in this study were hand-foot syndrome (HFS, 6/41, 14.6%), hypertension (5/41, 12.2%) and leukopenia (5/41, 12.2%).
Conclusions: Apatinib appears to be effective for the treatment of refractory mCRC with a manageable tolerability profile.
Methods: Patients with refractory mCRC received 500 mg of apatinib once a day in a 28-day cycle. Response was assessed using the RECIST 1.1 criteria, and toxicity was graded using CTCAE version 4.03. Survival analysis was performed by Kaplan-Meier method.
Results: Forty-one patients were included in the present study. Among these patients, 4 patients achieved partial response and 27 achieved stable disease. The response rate was 9.8%, and disease control rate was 75.6%. Median progression-free survival and overall survival were 2.9 months (95% CI: 2.4–3.5) and 8.9 months (95% CI: 8.0–9.8), respectively. The grade 3/4 toxicities observed in this study were hand-foot syndrome (HFS, 6/41, 14.6%), hypertension (5/41, 12.2%) and leukopenia (5/41, 12.2%).
Conclusions: Apatinib appears to be effective for the treatment of refractory mCRC with a manageable tolerability profile.
